<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31516114</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1476-1645</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>101</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>The American journal of tropical medicine and hygiene</Title>
          <ISOAbbreviation>Am J Trop Med Hyg</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Susceptibility of <i>Rickettsia rickettsii</i> to Tigecycline in a Cell Culture Assay and Animal Model for Rocky Mountain Spotted Fever.</ArticleTitle>
        <Pagination>
          <StartPage>1091</StartPage>
          <EndPage>1095</EndPage>
          <MedlinePgn>1091-1095</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.4269/ajtmh.19-0445</ELocationID>
        <Abstract>
          <AbstractText>Rocky Mountain spotted fever (RMSF), caused by <i>Rickettsia rickettsii</i>, is a severe tick-borne infection endemic to the Americas. Oral doxycycline is effective, but during severe life-threatening disease, intravenous therapy is recommended. Unfortunately, intravenous formulations of doxycycline are not always available. Therefore, we aimed to determine the susceptibility of <i>R. rickettsii</i> to an alternative parenteral agent, tigecycline, in vitro and in vivo. To determine the minimum inhibitory concentration of tigecycline, <i>R. rickettsii</i>-inoculated Vero cells were incubated with medium containing tigecycline. At various time points, monolayers were collected and <i>R. rickettsii</i> was quantified via real-time polymerase chain reaction (PCR). The growth of <i>R. rickettsii</i> was inhibited in the presence of ≥ 0.5 µg/mL of tigecycline. To determine the effectiveness of tigecycline in vivo, guinea pigs were inoculated with <i>R. rickettsii.</i> Five days after inoculation, they were treated twice daily with subcutaneous tigecycline 3.75 mg/kg or subcutaneous doxycycline 5 mg/kg. Treated animals improved, whereas untreated controls remained ill. Tissues were collected for quantitative PCR-determined bacterial loads on day 8. Median bacterial loads in the tigecycline group were less than those in untreated animals: liver (0 versus 2.9 × 10<sup>4</sup> copies/mg), lung (0 versus 8.3 × 10<sup>3</sup> copies/mg), skin (2.6 × 10<sup>2</sup> versus 2.2 × 10<sup>5</sup> copies/mg), spleen (0 versus 1.3 × 10<sup>4</sup> copies/mg), and testes (0 versus 1.0 × 10<sup>5</sup> copies/mg, respectively). There were no significant differences in the bacterial loads between doxycycline-treated versus tigecycline-treated guinea pigs. These data indicate that tigecycline is effective against <i>R. rickettsii</i> in cell culture and in an animal model of RMSF.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Blanton</LastName>
            <ForeName>Lucas S</ForeName>
            <Initials>LS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine-Infectious Diseases, University of Texas Medical Branch, Galveston, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilson</LastName>
            <ForeName>Nicholas M</ForeName>
            <Initials>NM</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, University of Texas Medical Branch, Galveston, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quade</LastName>
            <ForeName>Bethany R</ForeName>
            <Initials>BR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine-Infectious Diseases, University of Texas Medical Branch, Galveston, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Walker</LastName>
            <ForeName>David H</ForeName>
            <Initials>DH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Texas Medical Branch, Galveston, Texas.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>KL2 TR001441</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Am J Trop Med Hyg</MedlineTA>
        <NlmUniqueID>0370507</NlmUniqueID>
        <ISSNLinking>0002-9637</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>70JE2N95KR</RegistryNumber>
          <NameOfSubstance UI="D000078304">Tigecycline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058491" MajorTopicYN="N">Bacterial Load</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006168" MajorTopicYN="N">Guinea Pigs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012284" MajorTopicYN="N">Rickettsia rickettsii</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012373" MajorTopicYN="N">Rocky Mountain Spotted Fever</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078304" MajorTopicYN="N">Tigecycline</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31516114</ArticleId>
        <ArticleId IdType="pmc">PMC6838591</ArticleId>
        <ArticleId IdType="doi">10.4269/ajtmh.19-0445</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Yu X-J, Walker DH, 2005. 
Family I. Rickettsiaceae. Brenner DJ, Kreig NR, Stanley JT, eds. Bergey’s Manual of Systematic Bacteriology. New York, NY: Springer, 96–116.</Citation>
        </Reference>
        <Reference>
          <Citation>Parola P, et al. 
2013. 
Update on tick-borne rickettsioses around the world: a geographic approach. Clin Microbiol Rev
26: 657–702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3811236</ArticleId>
            <ArticleId IdType="pubmed">24092850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walker DH, Paddock CD, Dumler JS, 2008. 
Emerging and re-emerging tick-transmitted rickettsial and ehrlichial infections. Med Clin North Am
92: 1345–1361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19061755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amancio FF, Amorim VD, Chamone TL, Brito MG, Calic SB, Leite AC, Fraga GL, Ferraz ML, 2011. 
Epidemiological characteristics of Brazilian spotted fever in Minas Gerais state, Brazil, 2000–2008. Cad Saude Publica
27: 1969–1976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22031201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straily A, Drexler N, Cruz-Loustaunau D, Paddock CD, Alvarez-Hernandez G, 2016. 
Notes from the field: community-based prevention of Rocky Mountain spotted fever–Sonora, Mexico, 2016. MMWR Morb Mortal Wkly Rep
65: 1302–1303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27880753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biggs HM, et al. 
2016. 
Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis–United States. MMWR Recomm Rep
65: 1–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27172113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahon WA, Wittenberg JV, Tuffnel PG, 1970. 
Studies on the absorption and distribution of doxycycline in normal patients and in patients with severely impaired renal function. Can Med Assoc J
103: 1031–1034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1930710</ArticleId>
            <ArticleId IdType="pubmed">5494820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts DJ, Hall RI, 2013. 
Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin Drug Metab Toxicol
9: 1067–1084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23682923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauer G, Berens C, Projan SJ, Hillen W, 2004. 
Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother
53: 592–599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14985271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E, 2005. 
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis
41 (Suppl 5): S354–S367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16080073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E, 2005. 
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin–aztreonam. Clin Infect Dis
41 (Suppl 5): S341–S353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16080072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaseanu C, et al. 
2008. 
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis
61: 329–338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18508226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ, 2004. 
The glycylcyclines: a comparative review with the tetracyclines. Drugs
64: 63–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14723559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labruna MB, Whitworth T, Horta MC, Bouyer DH, McBride JW, Pinter A, Popov V, Gennari SM, Walker DH, 2004. 
Rickettsia species infecting Amblyomma cooperi ticks from an area in the state of Sao Paulo, Brazil, where Brazilian spotted fever is endemic. J Clin Microbiol
42: 90–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC321730</ArticleId>
            <ArticleId IdType="pubmed">14715737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edelstein PH, Weiss WJ, Edelstein MA, 2003. 
Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother
47: 533–540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151731</ArticleId>
            <ArticleId IdType="pubmed">12543655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanton LS, Walker DH, Bouyer DH, 2019. 
Rickettsia and Orientia. Carroll KC, Pfaller MA, Landry ML, McAdam AJ, Patel R, Richter SS, Warnock DW, eds. Manual of Clinical Microbiology. Washington, DC: ASM Press, 1149–1162.</Citation>
        </Reference>
        <Reference>
          <Citation>Dumler JS, 2012. 
Clincial disease: current treatment and new challenges. Palmer GH, Azad AF, eds. Intracellular Pathogens II: Rickettsiales. Washington, DC: ASM Press, 1–39.</Citation>
        </Reference>
        <Reference>
          <Citation>McDade JE, 1969. 
Determination of antibiotic susceptibility of Rickettsia by the plaque assay technique. Appl Microbiol
18: 133–135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC377915</ArticleId>
            <ArticleId IdType="pubmed">4896100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rolain JM, Maurin M, Vestris G, Raoult D, 1998. 
In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials. Antimicrob Agents Chemother
42: 1537–1541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC105641</ArticleId>
            <ArticleId IdType="pubmed">9660979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rolain JM, Stuhl L, Maurin M, Raoult D, 2002. 
Evaluation of antibiotic susceptibilities of three rickettsial species including Rickettsia felis by a quantitative PCR DNA assay. Antimicrob Agents Chemother
46: 2747–2751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC127393</ArticleId>
            <ArticleId IdType="pubmed">12183224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smadel JE, Jackson EB, Cruise AB, 1949. 
Chloromycetin in experimental rickettsial infections. J Immunol
62: 49–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18131595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maurin M, Raoult D, 1997. 
Bacteriostatic and bactericidal activity of levofloxacin against Rickettsia rickettsii, Rickettsia conorii, ‘Israeli spotted fever group rickettsia’ and Coxiella burnetii. J Antimicrob Chemother
39: 725–730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9222041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raoult D, Drancourt M, 1991. 
Antimicrobial therapy of rickettsial diseases. Antimicrob Agents Chemother
35: 2457–2462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC245412</ArticleId>
            <ArticleId IdType="pubmed">1810178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gotfried MH, Horn K, Garrity-Ryan L, Villano S, Tzanis E, Chitra S, Manley A, Tanaka SK, Rodvold KA, 2017. 
Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother
61: e01135–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5571291</ArticleId>
            <ArticleId IdType="pubmed">28696233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MacGowan AP, 2008. 
Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother
62 (Suppl 1): i11–i16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18684702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bella F, Espejo E, Uriz S, Serrano JA, Alegre MD, Tort J, 1991. 
Randomized trial of 5-day rifampin versus 1-day doxycycline therapy for Mediterranean spotted fever. J Infect Dis
164: 433–434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1856496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luciani F, Cione E, Corsonello A, Guido F, De Santis S, Cannataro R, Perri M, Caroleo MC, Cannataro AM, 2014. 
Spotted fever from Rickettsia typhi in an older woman: a case report from a geographic area where it would not be expected. Int J Infect Dis
27: 10–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25111740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuart BM, Pullen RL, 1945. 
Endemic (murine) typhus fever: clinical observations of 180 cases. Ann Intern Med
23: 17.</Citation>
        </Reference>
        <Reference>
          <Citation>del Sa DelFiol F, Junqueira FM, da Rocha MC, de Toledo MI, Filho SB, 2010. 
Rocky Mountain spotted fever in Brazil [article in Portuguese]. Rev Panam Salud Publica
27: 461–466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20721447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvarez-Hernandez G, Roldan JFG, Milan NSH, Lash RR, Behravesh CB, Paddock CD, 2017. 
Rocky Mountain spotted fever in Mexico: past, present, and future. Lancet Infect Dis
17: e189–e196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28365226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holman RC, Paddock CD, Curns AT, Krebs JW, McQuiston JH, Childs JE, 2001. 
Analysis of risk factors for fatal Rocky Mountain spotted fever: evidence for superiority of tetracyclines for therapy. J Infect Dis
184: 1437–1444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11709786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallerstein RO, Condit PK, Kasper CK, Brown JW, Morrison FR, 1969. 
Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA
208: 2045–2050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5818983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meloni G, Meloni T, 1996. 
Azithromycin vs. doxycycline for Mediterranean spotted fever. Pediatr Infect Dis J
15: 1042–1044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8933556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruiz Beltran R, Herrero Herrero JI, 1992. 
Evaluation of ciprofloxacin and doxycycline in the treatment of Mediterranean spotted fever. Eur J Clin Microbiol Infect Dis
11: 427–431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1425713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raoult D, Gallais H, De Micco P, Casanova P, 1986. 
Ciprofloxacin therapy for Mediterranean spotted fever. Antimicrob Agents Chemother
30: 606–607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC176489</ArticleId>
            <ArticleId IdType="pubmed">3789693</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
